bioAffinity Technologies, Inc. BIAFW

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
29/100
Developing

Ranked against 61 peers in Diagnostics & Research

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's … Full BIAFW analysis →

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.89). Improving FCF margin signals compounding operational leverage.
  • Expanding Operating Margin Operating margin trend is positive (score 0.93). Margin expansion confirms commercial leverage is building.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.25). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.13). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
20
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where BIAFW ranks in Diagnostics & Research

bioAffinity Technologies, Inc. ranks #50 of 62 scored companies in Diagnostics & Research by moat score — the top 81%. The widest moat in the group is IDEXX Laboratories, Inc. (IDXX) at 78/100.

# Company Moat score Rating
46 XWELL, Inc. XWEL 34/100 Developing
47 GRAIL, Inc. GRAL 32/100 Developing
48 Personalis, Inc. PSNL 30/100 Developing
49 bioAffinity Technologies, Inc. BIAF 29/100 Developing
50 bioAffinity Technologies, Inc. BIAFW 29/100 Developing
51 Atlantic International Corp. ATLN 29/100 Developing
52 Genetic Technologies Ltd GENE 25/100 Weak
53 ENDRA Life Sciences Inc. NDRA 19/100 Weak
54 Aclaris Therapeutics, Inc. ACRS 18/100 Weak

See every Medical Devices & Diagnostics company ranked by moat score →

How BIAFW scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 20 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 11 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 49 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 47 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 39 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 4 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding BIAFW's moat

What is bioAffinity Technologies, Inc. 's moat score?

bioAffinity Technologies, Inc. (BIAFW) scores 29 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #50 of 62 scored companies in Diagnostics & Research, the top 81%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is FCF Quality & Cash Conversion (49/100) and its weakest is Growth Durability (4/100).

How does bioAffinity Technologies, Inc. compare with other Diagnostics & Research companies?

bioAffinity Technologies, Inc. ranks #50 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are bioAffinity Technologies, Inc. (BIAF) at 29 just above it and Atlantic International Corp. (ATLN) at 29 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.

Why is bioAffinity Technologies, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for bioAffinity Technologies, Inc. ?

The Medical Devices & Diagnostics template measures 6 defenses, and BIAFW scores: Pricing Power & Consumable Moat (20), R&D Pipeline & Capital Returns (11), FCF Quality & Cash Conversion (49), Commercial Execution (47), Capital Structure & Resilience (39), Growth Durability (4). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000